Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: A single center experience

Mutations in the tumor suppressor gene TP53 are detected in 5–10% of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes. TP53 mutations have been associated with complex karyotypes, therapy-related malignancies, lower response rates to cytotoxic chemotherapy, and an overall adv...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leuk Lymphoma
Egile Nagusiak: Bewersdorf, Jan Philipp, Shallis, Rory M., Gowda, Lohith, Wei, Wei, Hager, Karl, Isufi, Iris, Kim, Tae Kon, Pillai, Manoj M., Seropian, Stuart, Podoltsev, Nikolai A., Gore, Steven D., Siddon, Alexa J., Zeidan, Amer M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7603787/
https://ncbi.nlm.nih.gov/pubmed/32362171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1759051
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak